全文获取类型
收费全文 | 5784篇 |
免费 | 422篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 239篇 |
妇产科学 | 136篇 |
基础医学 | 920篇 |
口腔科学 | 53篇 |
临床医学 | 621篇 |
内科学 | 1129篇 |
皮肤病学 | 62篇 |
神经病学 | 683篇 |
特种医学 | 140篇 |
外科学 | 592篇 |
综合类 | 38篇 |
预防医学 | 627篇 |
眼科学 | 52篇 |
药学 | 465篇 |
中国医学 | 26篇 |
肿瘤学 | 400篇 |
出版年
2024年 | 5篇 |
2023年 | 34篇 |
2022年 | 59篇 |
2021年 | 162篇 |
2020年 | 96篇 |
2019年 | 149篇 |
2018年 | 164篇 |
2017年 | 124篇 |
2016年 | 140篇 |
2015年 | 171篇 |
2014年 | 194篇 |
2013年 | 298篇 |
2012年 | 408篇 |
2011年 | 481篇 |
2010年 | 253篇 |
2009年 | 234篇 |
2008年 | 398篇 |
2007年 | 409篇 |
2006年 | 383篇 |
2005年 | 378篇 |
2004年 | 374篇 |
2003年 | 338篇 |
2002年 | 318篇 |
2001年 | 38篇 |
2000年 | 24篇 |
1999年 | 42篇 |
1998年 | 64篇 |
1997年 | 59篇 |
1996年 | 57篇 |
1995年 | 40篇 |
1994年 | 37篇 |
1993年 | 33篇 |
1992年 | 20篇 |
1991年 | 17篇 |
1990年 | 17篇 |
1989年 | 15篇 |
1988年 | 15篇 |
1987年 | 16篇 |
1986年 | 10篇 |
1985年 | 11篇 |
1984年 | 22篇 |
1983年 | 13篇 |
1982年 | 17篇 |
1981年 | 14篇 |
1980年 | 22篇 |
1979年 | 12篇 |
1978年 | 13篇 |
1977年 | 5篇 |
1973年 | 5篇 |
1972年 | 4篇 |
排序方式: 共有6229条查询结果,搜索用时 15 毫秒
81.
Monique VizelSchwartz 《Journal of surgical oncology》1981,17(1):57-61
The eighth case of osteoclastome-like giant cell carcinoma of the thyroid, and the first one to be treated with adriamycin in addition to surgery and radiation, is reported. This rare variant of anaplastic thryoid carcinoma appeared in a patient operated on for meningioma and treated for multiple myeloma with cranial radiation and chronic administration of cytoxan. 相似文献
82.
Edward Chow Lori Holden Joel Rubenstein Monique Christakis Katharina Sixel Marjan Vidmar Joel Finkelstein Charles Hayter Andrew Loblaw Rebecca Wong Ewa Szumacher Cyril Danjoux 《Radiotherapy and oncology》2004,70(3):291-294
Twenty-five patients with osteolytic metastases had computed tomography (CT) scans before and 3 months after palliative radiotherapy. The median % density change following single 8 Gy, 20 Gy/5#, 30 Gy/10# were: 128 (range 98–255), 141 (79–342), and 145 (65–235), respectively. It is feasible to evaluate remineralization of osteolytic lesions with palliative radiotherapy. 相似文献
83.
Hans-Peter Gschwind Ulrike Pfaar Felix Waldmeier Markus Zollinger Claudia Sayer Peter Zbinden Michael Hayes Rolf Pokorny Michael Seiberling Monique Ben-Am Bin Peng Gerhard Gross 《Drug metabolism and disposition》2005,33(10):1503-1512
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male healthy volunteers after a single oral dose of 239 mg of (14)C-labeled imatinib mesylate. Biological fluids were analyzed for total radioactivity, imatinib, and its main metabolite CGP74588. Metabolite patterns were determined by radio-high-performance liquid chromatography with off-line microplate solid scintillation counting and characterized by liquid chromatography-mass spectrometry. Imatinib treatment was well tolerated without serious adverse events. Absorption was rapid (t(max) 1-2 h) and complete with imatinib as the major radioactive compound in plasma. Maximum plasma concentrations were 0.921 +/- 0.095 mug/ml (mean +/- S.D., n = 4) for imatinib and 0.115 +/- 0.026 mug/ml for the pharmacologically active N-desmethyl metabolite (CGP74588). Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity. Imatinib was predominantly cleared through oxidative metabolism. Approximately 65 and 9% of total systemic exposure [AUC(0-24 h) (area under the concentration time curve) of radioactivity] corresponded to imatinib and CGP74588, respectively. The remaining proportion corresponded mainly to oxidized derivatives of imatinib and CGP74588. Imatinib and its metabolites were excreted predominantly via the biliary-fecal route. Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine). Approximately 28 and 13% of the dose in the excreta corresponded to imatinib and CGP74588, respectively. 相似文献
84.
David F. Moore Monique P. Gelderman Steven R. Fuhrmann Raphael Schiffmann Roscoe O. Brady & Ehud Goldin 《Acta paediatrica (Oslo, Norway : 1992)》2006,95(S451):69-71
Fabry disease is secondary to deficiency of the lysosomal enzyme α-galactosidase A, leading to altered glycosphingolipid metabolism and accumulation that is often associated with endothelial dysfunction. Current evidence suggests that there is impairment of the vascular nitric oxide pathway, with abnormalities evident in the cerebral circulation and in the dermal vasculature of patients with Fabry disease. Some of these findings have been confirmed in a mouse model of Fabry disease. The murine model, however, allows investigation of Fabry disease at a non-clinical level and a near complete investigation of biological processes within an affected tissue. This is of particular utility in allowing gene expression analysis of clinically inaccessible tissues such as the aorta.
Conclusion: Future developments in array technology for proteins and DNA single nucleotide polymorphism analysis, together with gene expression microarray analysis, may open a new chapter in our understanding of the biology of lysosomal storage disorders. 相似文献
Conclusion: Future developments in array technology for proteins and DNA single nucleotide polymorphism analysis, together with gene expression microarray analysis, may open a new chapter in our understanding of the biology of lysosomal storage disorders. 相似文献
85.
Wendy A G Stams Monique L den Boer H Berna Beverloo Jules P P Meijerink Elisabeth R van Wering Gritta E Janka-Schaub Rob Pieters 《Clinical cancer research》2005,11(8):2974-2980
PURPOSE: t(12;21)(p13; q22), present in approximately 25% of pediatric precursor B-ALL, is highly sensitivity to L-asparaginase and the prognosis depends on the intensity of the treatment protocol. This study analyzes the relationship between the mRNA expression of the genes and fusion products involved in t(12;21), in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, and long-term clinical outcome in t(12;21)+ acute lymphoblastic leukemia (ALL) patients. EXPERIMENTAL DESIGN: Long-term clinical outcome in 45 t(12;21)+ ALL patients was related to mRNA expression of TEL, AML1, TEL-AML1, and AML1-TEL, determined by real-time quantitative PCR, and the in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. RESULTS: A significant approximately 3.5-fold lower TEL expression in t(12;21)+ compared with t(12;21)- ALL samples (P = 0.006) and normal controls (P = 0.004) was found. Expression of AML1 did not differ between t(12;21)+ and t(12;21)- ALL. However, AML1 expression in the leukemic cells was 2-fold higher compared with normal controls (P = 0.02). The TEL-AML1 fusion product was expressed in all t(12;21)+ cases, whereas the reciprocal fusion product AML1-TEL was expressed in only 76%. High expression levels of TEL-AML1 [hazard ratio (HR), 1.3; 95% confidence interval (95% CI), 1.10-1.57; P = 0.003], AML1-TEL (HR, 4.9; 95% CI, 1.99-12.40; P = 0.001) and AML1 (HR, 1.1; 95% CI, 1.03-1.22; P = 0.006) were associated with a poor long-term clinical outcome within t(12;21)+ ALL. Cellular drug resistance towards prednisolone, vincristine, and L-asparaginase could not explain this predictive value. Multivariate analysis including age and WBC showed that only high AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL. CONCLUSION: High AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL. 相似文献
86.
Michel Ducreux Marc Ychou Agnès Laplanche Erick Gamelin Philippe Lasser Fares Husseini Fran?ois Quenet Frédéric Viret Jacques-Henri Jacob Valérie Boige Dominique Elias Jean-Robert Delperro Monique Luboinski 《Journal of clinical oncology》2005,23(22):4881-4887
PURPOSE: Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation of hepatic arterial infusion (HAI) of different drugs. Oxaliplatin combined with fluorouracil (FU) and leucovorin is effective in the treatment of colorectal cancer. In this context, a phase II study was conducted to evaluate concomitant administration of oxaliplatin by HAI and intravenous (IV) FU plus leucovorin according to the LV5FU2 protocol (leucovorin 200 mg/m(2), FU 400 mg/m(2) IV bolus, FU 600 mg/m(2) 22-hour continuous infusion on days 1 and 2 every 2 weeks). PATIENTS AND METHODS: Patients had metastatic colorectal cancer that was restricted to the liver and inoperable. The patients were not to have previously received oxaliplatin. After surgical insertion of a catheter in the hepatic artery, patients were treated with oxaliplatin 100 mg/m(2) HAI combined with FU + leucovorin IV according to the LV5FU2 protocol. Treatment was continued until disease progression or toxicity. Response was evaluated every 2 months. RESULTS: Twenty-eight patients were included, and 26 patients were treated. Two hundred courses of therapy were administered, and the median number of courses received was eight courses (range, zero to 20 courses). The most frequent toxicity consisted of neutropenia. The main toxicity related to HAI was pain. The intent-to-treat objective response rate was 64% (95% CI, 44% to 81%; 18 of 28 patients). With a median follow-up of 23 months, the median overall and disease-free survival times were 27 and 27 months, respectively. CONCLUSION: The combination of oxaliplatin HAI and FU + leucovorin according to the LV5FU2 protocol is feasible and effective in patients presenting with isolated hepatic metastases of colorectal cancer. 相似文献
87.
Dirk De Ruysscher Stofferinus Wanders Andre Minken Aniek Lumens Jacqueline Schiffelers Cissie Stultiens Serve Halders Liesbeth Boersma Angela van Baardwijk Tom Verschueren Monique Hochstenbag Gabriel Snoep Brad Wouters Sebastiaan Nijsten S?ren M Bentzen Marinus van Kroonenburgh Michel Ollers Philippe Lambin 《Radiotherapy and oncology》2005,77(1):5-10
BACKGROUND AND PURPOSE: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-simulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated. RESULTS: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2+/-2.0Gy with CT planning to 68.9+/-3.3Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3+/-1.5% for CT and 24.0+/-5.6% for PET-CT planning (P=0.01). CONCLUSIONS: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints. 相似文献
88.
89.
The power of positive deviance 总被引:1,自引:0,他引:1
David R Marsh Dirk G Schroeder Kirk A Dearden Jerry Sternin Monique Sternin 《British medical journal》2004,329(7475):1177-1179